Drug Trial Radar · NCT07154719
GLP-1R Actions on Muscle and the Skeleton
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 9, 2025
Primary completion
Feb 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- Pennington Biomedical Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.
Conditions
- Musculoskeletal Abnormalities
- Obesity
- Sarcopenic Obesity
- Osteoporosis
- Drug Effect
Interventions
TirzepatideDrug
GLP-1 based treatment for obesity
Lifestyle toolkitBehavioral
2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in fat free mass (FFM) using DXA imaging. FFM equals all body composition that is not fat mass. This includes bone, skeletal muscle, organs, water and all connective tissues. The unit of measurement is in kilograms (kg) at baseline, 3 and 6 mo.Time frame: Baseline and time 3, and 6 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Pennington Biomedical Research Center
Baton Rouge, Louisiana · Active not recruiting
MaineHealth Center for Clinical and Translational Science
Scarborough, Maine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.